Risk of MS Relapse Not Increased by COVID-19 Vaccine, Study Finds
Getting the Pfizer-BioNTech vaccine for COVID-19 does not increase the risk of multiple sclerosis (MS) relapses in the two…
Articles by Marisa Wexler, MS
Serious Infections in Adolescence Linked to Increased MS Risk
Experiencing serious infections during adolescence is tied to an increased risk of developing multiple sclerosis (MS) later in life,…
Early High-efficacy DMTs Linked to Better RRMS Outcomes in Sweden
People with relapsing-remitting multiple sclerosis (RRMS) in Sweden have lower rates of worsening disability than those who live in…
MS Patients in US Can Lack Key Insurance Coverage, Survey Warns
Most people with multiple sclerosis (MS) in the U.S. have health insurance, but many lack important other types of…
New Research Project Will Study Nerve Cell-Glia Communication
A new research project, funded by the National Institutes of Health (NIH), aims to better understand how different types of…
Variant in STK11 Gene Tied to Greater MS Risk for Black People in US
A variation in a gene called STK11, previously shown to increase the risk for multiple sclerosis (MS) among Caucasians, is…
PoNS Stimulation Device for MS Gait Problems Due in US Next Year
PoNS, a non-invasive devise to accompany physical therapy in multiple sclerosis (MS) patients with difficulty walking, will be available…
Smartphone App Floodlight Found to Reliably Measure MS Data
A smartphone-based app called Floodlight can reliably assess cognition, arm and hand function, and walking abilities in people with…
Trial Will Test Ocrevus on Arm, Hand Function in PPMS
A Phase 3 clinical trial testing the effect of Ocrevus (ocrelizumab) on upper limb disability progression in people with…
Probiotics Likely To Be of Help With RRMS, Meta-analysis Finds
Probiotic supplements could ease disability, lessen depression, and improve overall health in people with relapsing-remitting multiple sclerosis (MS), according…
Lemtrada Does Not Lead to Brain Bleeds, Small Belgian Study Says
Lemtrada (alemtuzumab) does not have a substantial effect on blood pressure or platelet counts, and does not lead to…
Heat, Variable Temperatures Found to Increase Risk of MS Hospital Visits
Visits to the hospital related to multiple sclerosis (MS) are more common when it’s hot or when temperatures are…
Many MS Patients Report Mistreatment by Caregivers
More than half of people with multiple sclerosis (MS) who require an informal caregiver have experienced abuse or mistreatment…
US Survey Finds High Rates of Dissatisfaction With Quality of Life, But Satisfaction With Healthcare
More than one-third of people with multiple sclerosis (MS) who responded to an online U.S.-based survey are dissatisfied with…
Metformin Seen to Aid Cognition, Brain Biology in MS Rat Model
Treatment with the diabetes medication metformin was seen to lessen cognitive impairment, improve coordination, and normalize neuronal activity in a…
Signaling Protein Seen to Help Promote Myelin-making Cells
A signaling protein called fractalkine helps to regulate the development of oligodendrocytes, cells of the nervous system responsible for making…
Gray Matter in Hippocampus Can Help Distinguish Between Two MS Types
Subtle changes in structure in the hippocampus — a region of the brain involved in processing memories — can differentiate…
Gilenya Started Earlier in RRMS Disease Course in Recent Years
People with relapsing-remitting multiple sclerosis (RRMS) have switched to treatment with Gilenya (fingolimod) at an earlier stage in…
NervGen Sets Advisory Board to Support Upcoming NVG-291 Trial
NervGen Pharma announced the formation of its multiple sclerosis (MS) clinical advisory board, a group of experts who…
Anti-CD20 Antibodies Reduce Myelin Loss in MS Rats
Treatment with anti-CD20 antibodies reduced the loss of myelin and improved the survival of neurons in a rat model of…
Trials of IMU-838 in RRMS, Progressive MS Start Later This Year
The U.S. Food and Drug Administration has cleared Immunic Therapeutics to initiate two clinical trials of its investigational medication IMU-838…
Ublituximab Quite ‘Reassuring’ as Potential MS Therapy, Experts Say
In clinical trials, the investigational anti-CD20 therapy ublituximab was the first to push the annualized relapse rate (ARR) below…
Early Use of High-efficacy DMTs Favor Lesser Disability Over Time
Long-term disability outcomes tend to be better in people with relapsing-remitting multiple sclerosis (RRMS) who are treated early on…
MS Symptoms Often Apparent Years Before Diagnosis
Many people with multiple sclerosis (MS) start experiencing symptoms of the disease several years before being diagnosed, a new study…
Long-term Kesimpta Use Not Seen in Trial to Depress Antibody Levels
Long-term use of Kesimpta (ofatumumab) among people with multiple sclerosis (MS) did not substantially lower their antibody levels, allowing…
Oral Aubagio Approved in EU for Children With RRMS, Ages 10-17
The European Commission (EC) has approved Aubagio (teriflunomide) for the treatment of children and adolescents, ages 10 to 17,…
Results: Ponvory Outperforms Aubagio in OPTIMUM Clinical Trial
In the OPTIMUM clinical trial, Ponvory (ponesimod) significantly outperformed Aubagio (teriflunomide) in reducing relapse rates, fatigue, and evidence of…
Data on T-cell Repertoire May Help in Understanding MS Development
T-cells in the fluid around the brain share a large percentage of receptors among different multiple sclerosis (MS) patients,…
FDA Rejects Expansion of Aubagio for Pediatric MS
The U.S. Food and Drug Administration (FDA) has rejected an application requesting the expansion of Aubagio (teriflunomide) for the…
Meaningful Cognitive Gains in Pediatric MS Captured Using Pencil-Paper Test
A computer-based training program that exercises distinct components of attention and working memory can improve cognition in young people with…